ZA202002247B - Treating ige-mediated allergic diseases - Google Patents
Treating ige-mediated allergic diseasesInfo
- Publication number
- ZA202002247B ZA202002247B ZA2020/02247A ZA202002247A ZA202002247B ZA 202002247 B ZA202002247 B ZA 202002247B ZA 2020/02247 A ZA2020/02247 A ZA 2020/02247A ZA 202002247 A ZA202002247 A ZA 202002247A ZA 202002247 B ZA202002247 B ZA 202002247B
- Authority
- ZA
- South Africa
- Prior art keywords
- allergic diseases
- mediated allergic
- treating ige
- ige
- treating
- Prior art date
Links
- 208000026935 allergic disease Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762579416P | 2017-10-31 | 2017-10-31 | |
| PCT/CN2018/112714 WO2019085902A1 (en) | 2017-10-31 | 2018-10-30 | Treating ige-mediated allergic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202002247B true ZA202002247B (en) | 2022-01-26 |
Family
ID=66332803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/02247A ZA202002247B (en) | 2017-10-31 | 2020-05-04 | Treating ige-mediated allergic diseases |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11439682B2 (enExample) |
| EP (1) | EP3703753A4 (enExample) |
| JP (1) | JP7286665B2 (enExample) |
| KR (1) | KR102859911B1 (enExample) |
| CN (1) | CN111741768B (enExample) |
| AU (1) | AU2018360999A1 (enExample) |
| BR (1) | BR112020008488A2 (enExample) |
| CA (1) | CA3079992A1 (enExample) |
| IL (1) | IL277911B2 (enExample) |
| MX (1) | MX421215B (enExample) |
| TW (1) | TWI821209B (enExample) |
| WO (1) | WO2019085902A1 (enExample) |
| ZA (1) | ZA202002247B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024513039A (ja) * | 2021-04-02 | 2024-03-21 | ワンネス・バイオテック・カンパニー・リミテッド | 高濃度の抗体製剤 |
| CN118119641A (zh) * | 2021-10-12 | 2024-05-31 | 联合生物制药股份有限公司 | Ige调节的疾病的治疗 |
| CN114028731B (zh) * | 2021-12-10 | 2024-01-26 | 固安翌光科技有限公司 | 腰部塑形光疗装置 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5514776A (en) | 1987-12-31 | 1996-05-07 | Tanox Biosystems, Inc. | Peptides representing antigenic epitopes of dog IgE present on B cell but not basophil surface |
| US5260416A (en) | 1987-12-31 | 1993-11-09 | Tanox Biosystems, Inc. | Antigenic epitopes present on membrane-bound but not secreted IgE |
| US5089603A (en) | 1989-06-21 | 1992-02-18 | Tanox Biosystems, Inc. | Antigenic epitopes present on membrane-bound but not secreted iga |
| US5252467A (en) | 1987-12-31 | 1993-10-12 | Tanox Biosystems, Inc. | Method of making antibodies to antigenic epitopes of IGE present on B cells but not basophil cell surface or secreted, soluble IGE |
| US5342924A (en) | 1987-12-31 | 1994-08-30 | Tanox Biosystems, Inc. | Extracellular segments of human ε immunoglobulin anchoring peptides and antibodies specific therefor |
| US5079344A (en) | 1989-06-21 | 1992-01-07 | Tanox Biosystems, Inc. | Antigenic epitopes present on membrane-bound but not secreted IgA |
| US5362643A (en) | 1989-06-21 | 1994-11-08 | Tanox Biosystems | Antibodies to epitopes present on membrane-bound but not secreted IGA |
| US5614611A (en) | 1987-12-31 | 1997-03-25 | Tanox Biosystems, Inc. | Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils |
| US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
| US5231026A (en) | 1987-12-31 | 1993-07-27 | Tanox Biosystems, Inc. | DNA encoding murine-human chimeric antibodies specific for antigenic epitopes of IgE present on the extracellular segment of the membrane domain of membrane-bound IgE |
| US5422258A (en) | 1987-12-31 | 1995-06-06 | Tanox Biosystems, Inc. | Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils |
| US5254671A (en) | 1990-04-27 | 1993-10-19 | Tanox Biosystems, Inc. | Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor |
| US5690934A (en) | 1987-12-31 | 1997-11-25 | Tanox Biosystems, Inc. | Peptides relating to the extracellular membrane-bound segment of human alpha chain |
| US5274075A (en) | 1987-12-31 | 1993-12-28 | Tanox Biosystems, Inc. | Newly identified human epsilon immunoglobulin peptides and related products |
| US5449760A (en) | 1987-12-31 | 1995-09-12 | Tanox Biosystems, Inc. | Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils |
| US5484907A (en) | 1989-06-21 | 1996-01-16 | Tanox Biosystems, Inc. | Nucleotides coding for the extracellular membrane-bound segment of IgA |
| DE122006000007I2 (de) | 1987-12-31 | 2008-03-27 | Tanox Inc | -tragenden b-lymphocyten befinden. |
| US5292867A (en) | 1988-11-16 | 1994-03-08 | Tanox Biosystems, Inc. | Chimeric monoclonal antibodies which bind to the extracellular segment of the membrane-bound domain of a human membrane-bound immunoglobulin |
| GB8913737D0 (en) | 1989-06-15 | 1989-08-02 | Univ Birmingham | A novel anti-allergy treatment |
| US5310875A (en) | 1989-06-21 | 1994-05-10 | Tanox Biosystems, Inc. | Peptides corresponding to membrane-bound IgA |
| ES2100892T3 (es) | 1989-09-15 | 1997-07-01 | Tanox Biosystems Inc | Tratamiento de enfermedades autoinmunitarias. |
| AU645783B2 (en) | 1990-01-23 | 1994-01-27 | Tanox Biosystems, Inc. | Extracellular segments of human epsilon immunoglobulin anchoring peptides and antibodies specific therefor |
| US5281699A (en) | 1990-06-01 | 1994-01-25 | Tanox Biosystems, Inc. | Treating B cell lymphoma or leukemia by targeting specific epitopes on B cell bound immunoglobulins |
| US5298420A (en) | 1990-08-03 | 1994-03-29 | Tanox Biosystems, Inc. | Antibodies specific for isotype specific domains of human IgM and human IgG expressed or the B cell surface |
| AU9016591A (en) | 1990-10-25 | 1992-05-26 | Tanox Biosystems, Inc. | Glycoproteins associated with membrane-bound immunoglobulins as antibody targets on B cells |
| SE9102808L (sv) | 1991-09-26 | 1993-03-27 | Lars T Hellman Inst F Immunolo | Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner |
| CA2203165A1 (en) | 1994-10-25 | 1996-05-02 | United Biomedical, Inc. | Synthetic ige membrane anchor peptide immunogens for the treatment of allergy |
| AU3515597A (en) | 1997-05-30 | 1998-12-30 | Tanox Biosystems, Inc. | Inhibition of antigen-specific ige production by antigen coupled to membrane igepetide |
| EP2361635A3 (en) | 2000-08-30 | 2011-09-14 | Pfizer Products Inc. | Anti IgE vaccines |
| AUPS158502A0 (en) | 2002-04-08 | 2002-05-16 | Dermcare-Vet Pty Ltd | Allergic dermatitis composition and method of treatment |
| US8137670B2 (en) | 2005-09-29 | 2012-03-20 | Medimmune, Llc | Method of identifying membrane IgE specific antibodies and use thereof for targeting IgE producing precursor cells |
| US20090220416A1 (en) | 2006-05-03 | 2009-09-03 | Sydney Welt | Immunoglobulin associated cell-surface determinants in the treatment of b-cell disorders |
| NZ580553A (en) | 2007-03-22 | 2012-05-25 | Genentech Inc | Apoptotic anti- ige antibodies binding the membrane-bound ige |
| KR101529160B1 (ko) * | 2009-02-25 | 2015-06-16 | 아카데미아 시니카 | Ｂ 림프구 상의 인간 ｍＩｇＥ에 결합 가능한 항-ＣεｍＸ 항체 |
| EP2504030A4 (en) * | 2009-11-24 | 2013-06-26 | Alderbio Holdings Llc | IL-6 ANTAGONISTS FOR INCREASING ALBUMIN AND / OR REDUCING CRP |
| US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| WO2011108008A2 (en) | 2010-03-04 | 2011-09-09 | Transgene Biotek Ltd. | Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1 |
| CN104603150A (zh) * | 2012-04-20 | 2015-05-06 | 中央研究院 | 与CH4和CεmX结构域之间的连接处结合的抗mIgE抗体 |
| ES2981062T3 (es) | 2012-09-07 | 2024-10-07 | Regeneron Pharma | Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R |
| JP6068582B2 (ja) * | 2015-08-07 | 2017-01-25 | アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ | Ｂリンパ球上のヒトｍＩｇＥに結合可能な抗ＣεｍＸ抗体 |
-
2018
- 2018-10-30 KR KR1020207014545A patent/KR102859911B1/ko active Active
- 2018-10-30 CA CA3079992A patent/CA3079992A1/en active Pending
- 2018-10-30 JP JP2020543683A patent/JP7286665B2/ja active Active
- 2018-10-30 EP EP18873803.3A patent/EP3703753A4/en active Pending
- 2018-10-30 WO PCT/CN2018/112714 patent/WO2019085902A1/en not_active Ceased
- 2018-10-30 AU AU2018360999A patent/AU2018360999A1/en not_active Abandoned
- 2018-10-30 IL IL277911A patent/IL277911B2/en unknown
- 2018-10-30 MX MX2020004469A patent/MX421215B/es unknown
- 2018-10-30 BR BR112020008488-3A patent/BR112020008488A2/pt unknown
- 2018-10-30 CN CN201880084604.5A patent/CN111741768B/zh active Active
- 2018-10-31 TW TW107138583A patent/TWI821209B/zh active
-
2020
- 2020-04-29 US US16/862,512 patent/US11439682B2/en active Active
- 2020-05-04 ZA ZA2020/02247A patent/ZA202002247B/en unknown
-
2022
- 2022-09-09 US US17/930,799 patent/US12083161B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020117749A3 (enExample) | 2022-01-31 |
| EP3703753A4 (en) | 2021-08-18 |
| US11439682B2 (en) | 2022-09-13 |
| MX421215B (es) | 2025-02-10 |
| RU2020117749A (ru) | 2021-12-02 |
| KR102859911B1 (ko) | 2025-09-16 |
| CA3079992A1 (en) | 2019-05-09 |
| MX2020004469A (es) | 2020-09-07 |
| US20230100100A1 (en) | 2023-03-30 |
| JP2021501213A (ja) | 2021-01-14 |
| TWI821209B (zh) | 2023-11-11 |
| WO2019085902A1 (en) | 2019-05-09 |
| IL277911B1 (en) | 2025-03-01 |
| TW201929899A (zh) | 2019-08-01 |
| BR112020008488A2 (pt) | 2020-10-20 |
| KR20200110302A (ko) | 2020-09-23 |
| IL277911B2 (en) | 2025-07-01 |
| EP3703753A1 (en) | 2020-09-09 |
| US12083161B2 (en) | 2024-09-10 |
| CN111741768A (zh) | 2020-10-02 |
| IL277911A (en) | 2020-11-30 |
| US20200297815A1 (en) | 2020-09-24 |
| CN111741768B (zh) | 2024-12-27 |
| JP7286665B2 (ja) | 2023-06-05 |
| AU2018360999A1 (en) | 2020-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283799B (en) | Compounds and methods for the treatment of RNA-mediated diseases | |
| IL269371A (en) | Treatment methods | |
| IL246791A0 (en) | Compositions and methods for treating eye diseases | |
| IL255421A0 (en) | Preparations and methods for the treatment of neurodegenerative disease | |
| IL269106A (en) | Methods for the treatment of neurodegenerative diseases | |
| EP3448263A4 (en) | Electrotherapeutic treatment | |
| SG11201704829QA (en) | Methods and compositions for treating brain diseases | |
| GB2561747B (en) | Composition for treating motor neuron diseases and use thereof | |
| IL277911A (en) | Treatment of IGE-mediated allergic diseases | |
| IL269698B (en) | Methods for preventing or treating eye diseases | |
| GB201714307D0 (en) | Treatment of neurodegenerative diseases | |
| IL253847A0 (en) | Methods of treating diseases | |
| EP3265103A4 (en) | Compositions and methods for treating ocular diseases | |
| IL259381B (en) | Mirabegron for the treatment of retinal diseases | |
| PT3302499T (pt) | Tratamento de doenças mitocondriais | |
| PL3182980T3 (pl) | Leczenie chorób niedoboru glikozylacji | |
| GB201718985D0 (en) | Treatment | |
| EP3474876A4 (en) | TREATMENT OF MORBUS CANAVAN | |
| SG11202005278PA (en) | Compounds for treating eye diseases and methods thereof | |
| ZA201802201B (en) | Novel formulation and treatment methods | |
| GB201714303D0 (en) | Treatment of neurodegenerative diseases | |
| GB201714311D0 (en) | Treatment of neurodegenerative diseases | |
| IL246608A0 (en) | Preparations and methods for treating heart disease | |
| PL3302463T3 (pl) | Zastosowanie 3 deoksyantocyjanidyn w leczeniu chorób oczu | |
| GB201500555D0 (en) | Method and device for the treatment of diseases |